ClinicalTrials.gg
CompletedNCT03019575Updated May 23, 2024Results posted

Efficacy and Safety of Corifollitropin Alfa (MK-8962) in Combination With Human Chorionic Gonadotropin (hCG) in Adolescent Males With Hypogonadotropic Hypogonadism (HH) (MK-8962-043)

A Phase 3 interventional study of Corifollitropin alfa and hCG in Hypogonadotropic Hypogonadism, sponsored by Organon and Co. Completed at 15 sites in 6 countries. Open to male participants aged 14 Years to 17 Years. Per ClinicalTrials.gov, last updated 2024-05-23.

Sponsored by Organon and Co · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
17
Allocation
Not applicable
Ages
14 Years to 17 Years
Sex
Male
01

Study summary

The purpose of the study is to investigate whether corifollitropin alfa (MK-8962), administered alone for 12 weeks and then in combination with human chorionic gonadotropin (hCG) for 52 weeks, increases the testicular volume in adolescent males aged 14 to \<18. In addition, the study will evaluate participants for safety, tolerability and for the development of corifollitropin alfa antibodies. No formal hypothesis will be tested for this estimation study

02

Conditions studied

  • Hypogonadotropic Hypogonadism

Browse trials for

03

In context

Hypogonadism

320 studies on the registry are indexed under Hypogonadism; 39 are open to participants now.

This study's enrollment of 17 is below the median of 50 across 243 interventional studies indexed under Hypogonadism.

Browse Hypogonadism studies →

Lead sponsor

Organon and Co is the lead sponsor of 505 studies on the registry; none are open to participants now.

Of its 23 completed or terminated interventional studies of FDA-regulated products, 18 (78%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
14 Years to 17 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have legal representative who understands the study procedures, alternative treatments available and risks involved with the study, and voluntarily agrees to the individual's participation by giving written , and the individual has an age-appropriate understanding of the same to give informed written assent if applicable.
  • Diagnosed with hypogonadotropic hypogonadism (either isolated or associated with panhypopituitarism), either congenital or acquired with onset prior to puberty.
  • Have bilateral pre-gonadarche testes as defined by testicular volume \<4.0 mL for each testicle, as determined by ultrasound and assessed by the investigator (if qualified) or local radiologist with appropriate training and expertise in reading testicular ultrasound. Note: participants with a volume of \<4.0 mL in one testicle and a volume of 4-8 mL in the other testicle are considered to be pre-gonadarche and may participate, if there is no history or evidence of a primary testicular disorder (see Exclusion Criteria 1 and 2).
  • Have circulating levels of total testosterone (Total T) less than the lower limit of normal (LLN) of 8.3 nmol/L as specified by the central lab for a young healthy adult male.
  • Have follicle stimulating hormone (FSH) ≤2 IU/L and luteinizing hormone (LH) ≤2 IU/L.
  • Have inhibin-B levels ≤35 pg/mL. (Note: if individual has inhibin-B levels >35 pg/mL, but meets all of the other inclusion/exclusion criteria, either a GnRH agonist (GnRHa) stimulation test or GnRH IV infusion test may be performed.
  • In good general physical and mental health, in the opinion of the investigator/sponsor, as assessed by physical examination and routine clinical laboratory tests.
  • Have a parent/guardian able and willing to support the individual's participation by supporting adherence to study drug dosing and visit schedules.

Exclusion criteria

Exclusion Criteria:

  • Have a history of bilateral cryptorchidism (maldescended testes) or unilateral cryptorchidism treated after the age of 2 years.
  • Have a history or presence of testicular problems (e.g., epididymitis, orchitis, testicular torsion, varicocele Grade III, testicular atrophy, occlusive azoospermia, etc.) that would impair participants response to treatment or has had known damage or injury to the vas deferens.
  • Had any previous treatment with GnRH, gonadotropins (e.g., hCG, FSH) or androgens (e.g., testosterone, etc.). Note: Use of GnRH and gonadotropins for diagnostic testing purposes only is allowed. Participants with use of hCG and androgen therapy prior to the age of 2 years old can be included in the trial. Participants with transient use of androgens (i.e., for less than 2 weeks) that was stopped at least 6 months prior to signing can also be included in the trial.
  • Has an untreated or inadequately treated pituitary or hypothalamic tumor.
  • Have uncontrolled endocrinopathies, including thyroid, adrenal, and pituitary disorders not on stable replacement therapies.
  • Has a history of active pituitary hypersecretion as evidenced by hyperprolactinemia or Cushing's disease, acromegaly, or any other active pituitary hypersecretion syndrome. (Note: Individuals who have been treated and are clinically stable, with no evidence of hypersecretion for at least 12 months prior to screening, may participate.
  • Has had hypophysectomy within 12 months to the start of screening.
  • Has history of oncologic chemotherapy treatment.
  • Has had brain radiotherapy within 12 months of start of treatment for a primary tumor, or any history of brain radiotherapy for disease.
  • Has diabetes mellitus.
  • Has history of (HIV).
  • Has renal insufficiency, as determined by investigator, based on serum creatinine, blood urea nitrogen, and estimated .
  • Has clinically significant liver disease, including active viral hepatitis or cirrhosis. Individuals with a prior history of liver disease which is now inactive or successfully treated may be enrolled if all liver function values performed within the past year have been normal and within the normal range at Visit 1.
  • Has had a recent history of recreational or illicit drug use, including marijuana; or routinely consumes >2 alcoholic drinks per day or >14 alcoholic drinks per week, or engages in binge drinking.
  • Has an allergy/sensitivity to gonadotropins or its/their .
  • Has used an drug and/or participated in any other clinical trial within the past 8 weeks (prior to Visit 2), or will participate in any other clinical trials (excluding surveys) during the course of this trial.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    Corifollitropin alfa (CFA)+human Chorionic Gonadotropin (hCG)

    Participants received 100 μg (if body weight was ≤60 kg) or 150 μg (if body weight was \>60 kg) of CFA as a subcutaneous (SC) injection once every 2 weeks for 64 Weeks (Day 1, Week 0 through Week 64) and 500-5000 IU of hCG reconstituted with 1 ml of 0.9% sodium chloride solution, as a SC injection twice a week for 52 weeks (last day of Week 12 through Week 64). The total treatment duration was 64 Weeks.

    Drug: Corifollitropin alfa · Drug: hCG

Interventions

  • CFA administered 100 μg (if body weight ≤60 kg) or 150 μg (if body weight \>60 kg) by SC injection, once every 2 weeks for 64 weeks (Day 1, Week 0 through Week 64).

    Also known as: MK-8962, Elonva

  • DrughCG

    hCG 500-5000 IU reconstituted with 1 ml of 0.9% sodium chloride solution, as a SC injection twice a week for 52 weeks (last day of Week 12 through Week 64).

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Log-Transformed Testicular Volume (TV) to Week 64

    Participants underwent testicular ultrasound of left and right testes at pre-specified time points to measure TV. TV was measured as the sum of volumes of left and right testes. The linear mixed model with a fixed effect for baseline and Week 64 and a random effect for participant was used to calculate the mean change in log-transformed TV and associated 95% confidence intervals (CIs) from baseline to Week 64. The geometric mean ratio and its 95% CIs for TV were obtained by exponentiation. The ratio \> 1 indicated an increase in TV from baseline.

    Time frame: Baseline and Week 64

  2. Number of Participants Who Experienced an Adverse Event (AE)

    An adverse event was defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. The number of participants who experienced an AE was reported.

    Time frame: Up to approximately 71 Weeks

  3. Number of Participants Who Discontinued Study Treatment Due to an AE

    An adverse event was defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. The number of participants who discontinued study treatment due to an AE was reported.

    Time frame: Up to approximately 64 Weeks

  4. Percentage of Participants With Anti-Corifollitropin Alfa (CFA) Antibodies

    Blood samples were collected at pre-specified time points to assess anti-CFA antibodies. The percentage of participants with anti-CFA antibodies after administration of CFA were reported.

    Time frame: Up to approximately 71 Weeks

Secondary outcomes

  1. Change From Baseline in Serum Inhibin B Concentration to Week 64

    Serum Inhibin B concentration is a surrogate marker for spermatogenesis in males. Blood samples were collected at baseline and Week 64 post dose to report the mean change from baseline in serum inhibin concentration to Week 64. A mean change from baseline in serum inhibin B concentration to Week 64 was reported. A positive value indicated a higher serum inhibin concentration level.

    Time frame: Baseline and Week 64

  2. Growth Velocity at Week 36

    Growth velocity is the rate of change in height measurement and is a marker for pubertal progress. Height was measured using a wall-mounted calibrated stadiometer. A mixed model was used to assess the overall growth velocity slope over the 36-week treatment period using the slopes estimated from an overall mixed random intercept and random slope model of height (cm) and time (yr) and age as covariates.

    Time frame: Week 36

  3. Growth Velocity at Week 64

    Growth velocity is the rate of change in height measurement and is a marker for pubertal progress. Height was measured using a wall-mounted calibrated stadiometer. A mixed model was used to assess the overall growth velocity slope over the 64-week treatment period using the slopes estimated from an overall mixed random intercept and random slope model of height (cm) and time (year) and age as covariates.

    Time frame: Week 64

  4. Change From Baseline in Tanner Stage (TS) of Pubertal Development for Pubic Hair to Week 12, Week 36, and Week 64

    Male participants were assessed clinically for pubertal development using the TS for pubic hair (range: Tanner I-V). TS describes sexual maturity stages (no better or worse outcome) as: Tanner I: prepubertal state, Tanner II: small amount of long, downy hair with slight pigmentation at the base of the penis and scrotum, Tanner III: hair becomes more coarse and curly, and begins to extend laterally, Tanner IV: adult-like hair quality, extending across pubis but sparing medial thighs and Tanner V: hair extends to medial surface of the thigh. The number of participants in each Tanner stage at baseline and categorical change from baseline in Tanner stages to Weeks 12, 36 and 64 were reported.

    Time frame: Baseline, Week 12, Week 36, and Week 64

  5. Change From Baseline in TS of Pubertal Development for Genital Growth to Week 12, Week 36, and Week 64

    Male participants were assessed clinically for pubertal development using TS for genital growth (range: Tanner I-V). TS describes sexual maturity stages (no better or worse outcome) as: Tanner I: prepubertal (TV \<1.5 ml; small penis), Tanner II: TV 1.6-6ml; skin on scrotum thins, reddens and enlarges; penis length unchanged, Tanner III: TV 6-12ml; scrotum enlarges further; penis begins to lengthen Tanner IV: TV 12-20ml; scrotum enlarges further and darkens; penis increases in length and circumference, and Tanner V: TV \>20ml; adult scrotum and penis. The number of participants in each Tanner stage at baseline and categorical change from baseline in Tanner stages to Weeks 12, 36 and 64 were reported.

    Time frame: Baseline, Week 12, Week 36, and Week 64

  6. Mean Serum Concentration of CFA

    Blood samples were collected at pre-specified time points (Day 1 (predose, 6-24 hours postdose after 1st dose), Day 3 (32-52 hours postdose after 1st dose), Day 5 (72-120 hours postdose after 1st dose), Day 8 (144-192 hours postdose after 1st dose), Day 11 (216-244 hours postdose after 1st dose), Day 29 (predose prior to 2nd dose; no hCG), Day 85 (predose, prior to 4th dose; no hCG), Day 169 (predose prior to 7th dose; with hCG co-administration), Day 253 (predose prior to 10th dose with hCG co-administration), Day 337 (predose prior to 13th dose; with hCG co-administration), Days 449 and 456 (postdose)) to report the mean serum concentration of CFA.

    Time frame: Day 1: predose, 6-24 hours postdose; Day 3: 32-52 hours postdose; Day 5: 72-120 hours postdose; Day 8: 144-192 hours postdose; Day 11: 216-244 hours postdose; Days 29, 85, 169, 253, 337: predose; Days 449, 456: postdose

  7. Change From Baseline in Testicular Echogenicity to Week 12, Week 36, and Week 64

    Testicular Echogenicity was determined by evaluating the sonographic patterns obtained on testicular ultrasound of right and left testes at baseline, Week 12, Week 36 and 64. The sonographic patterns were assessed by central imaging unit by an independent radiologist and categorized as Hypoechoic (decreased echogenicity as compared to echogenicity at baseline), Isoechoic (same echogenicity as compared to echogenicity at baseline) and Hyperechoic (increased echogenicity as compared to echogenicity at baseline). The number of participants with a sonographic pattern at Weeks 12, 36 and 64 were reported.

    Time frame: Baseline, Week 12, Week 36, and Week 64

  8. Change From Baseline in Luteinizing Hormone (LH) to Week 12, Week 36, and Week 64

    LH is a gonadotropin secreted from the anterior pituitary and is a marker for spontaneous puberty. Blood samples were collected at baseline, Week 12, Week 36 and Week 64 to report the mean change from baseline in LH level to Weeks 12, 36 and 64.

    Time frame: Baseline, Week 12, Week 36, and Week 64

  9. Change From Baseline in Calculated Free Testosterone (T) to Week 12, Week 36, and Week 64

    Blood samples were collected at baseline, Week 12, Week 36 and Week 64 to report the mean change from baseline in T level to Weeks 12, 36 and 64. The change from baseline in T level to Week 12, 36, and 64 could not be calculated as planned because only 2 participants had baseline T level values which were insufficient to provide the trend change from baseline in T level to Week 12, 36, and 64.

    Time frame: Baseline, Week 12, Week 36, and Week 64

  10. Change From Baseline in Total Testosterone (Total T) to Week 12, Week 36, and Week 64

    Total T is a marker for progress of puberty in males. Total T levels increase during puberty as the testes respond to the gonadotropins. Blood samples were collected at baseline, Week 12, Week 36 and Week 64 post dose to report the mean change from baseline in Total T level to Weeks 12, 36 and 64. A negative value indicated a lower Total T level.

    Time frame: Baseline, Week 12, Week 36, and Week 64

  11. Change From Baseline in Estradiol (E2) to Week 12, Week 36, and Week 64

    E2 levels rise during puberty in males when some of the T secreted is aromatized. Blood samples were collected at baseline, Week 12, Week 36 and Week 64 to report the mean change from baseline in E2 level to Weeks 12, 36 and 64. A positive value indicated a higher E2 level.

    Time frame: Baseline, Week 12, Week 36, and Week 64

  12. Change From Baseline in Sex Hormone-Binding Globulin (SHBG) to Week 12, Week 36, and Week 64

    SHBG is a blood protein that controls the amount of T body tissues in males. SHBG is regulated by the ratio of T and E2 levels in addition to other factors (thyroid hormone status, dietary factors, certain diseases and medications). Blood samples were collected at baseline, Week 12, Week 36 and Week 64 to report the mean change from baseline in SHBG level to Weeks 12, 36 and 64. A negative value indicated a lower SHBG level.

    Time frame: Baseline, Week 12, Week 36, and Week 64

  13. Change From Baseline in Anti-Müllerian Hormone (AMH) to Week 12, Week 36, and Week 64

    AMH is a marker for progress of puberty in males. Blood samples were collected at baseline, Week 12, Week 36 and Week 64 to report the mean change from baseline in AMH level to Weeks 12, 36 and 64. A negative value indicated a lower AMH level.

    Time frame: Baseline, Week 12, Week 36, and Week 64

07

Results

Posted Apr 8, 2021

Participant flow

Participant flow — Overall Study
MilestoneCorifollitropin Alfa (CFA)+Human Chorionic Gonadotropin (hCG)
Started17
Completed17
Not completed0

Outcome measures

PrimaryChange From Baseline in Log-Transformed Testicular Volume (TV) to Week 64

Participants underwent testicular ultrasound of left and right testes at pre-specified time points to measure TV. TV was measured as the sum of volumes of left and right testes. The linear mixed model with a fixed effect for baseline and Week 64 and a random effect for participant was used to calculate the mean change in log-transformed TV and associated 95% confidence intervals (CIs) from baseline to Week 64. The geometric mean ratio and its 95% CIs for TV were obtained by exponentiation. The ratio \> 1 indicated an increase in TV from baseline.

Time frame:
Baseline and Week 64
Reported as:
Mean · mL
Change From Baseline in Log-Transformed Testicular Volume (TV) to Week 64
mLCorifollitropin Alfa (CFA)+Human Chorionic Gonadotropin (hCG)
Baseline1.5 ± 0.7
Week 6414.5 ± 6.8
Statistical analysis
  • Corifollitropin Alfa (CFA)+Human Chorionic Gonadotropin (hCG) · Geometric mean ratio: 9.43 · 95% CI 7.44 to 11.97
PrimaryNumber of Participants Who Experienced an Adverse Event (AE)

An adverse event was defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. The number of participants who experienced an AE was reported.

Time frame:
Up to approximately 71 Weeks
Reported as:
Count of participants · Participants
Number of Participants Who Experienced an Adverse Event (AE)
ParticipantsCorifollitropin Alfa (CFA)+Human Chorionic Gonadotropin (hCG)
Number of Participants Who Experienced an Adverse Event (AE)16
PrimaryNumber of Participants Who Discontinued Study Treatment Due to an AE

An adverse event was defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. The number of participants who discontinued study treatment due to an AE was reported.

Time frame:
Up to approximately 64 Weeks
Reported as:
Count of participants · Participants
Number of Participants Who Discontinued Study Treatment Due to an AE
ParticipantsCorifollitropin Alfa (CFA)+Human Chorionic Gonadotropin (hCG)
Number of Participants Who Discontinued Study Treatment Due to an AE1
PrimaryPercentage of Participants With Anti-Corifollitropin Alfa (CFA) Antibodies

Blood samples were collected at pre-specified time points to assess anti-CFA antibodies. The percentage of participants with anti-CFA antibodies after administration of CFA were reported.

Time frame:
Up to approximately 71 Weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants With Anti-Corifollitropin Alfa (CFA) Antibodies
Percentage of ParticipantsCorifollitropin Alfa (CFA)+Human Chorionic Gonadotropin (hCG)
Percentage of Participants With Anti-Corifollitropin Alfa (CFA) Antibodies0
SecondaryChange From Baseline in Serum Inhibin B Concentration to Week 64

Serum Inhibin B concentration is a surrogate marker for spermatogenesis in males. Blood samples were collected at baseline and Week 64 post dose to report the mean change from baseline in serum inhibin concentration to Week 64. A mean change from baseline in serum inhibin B concentration to Week 64 was reported. A positive value indicated a higher serum inhibin concentration level.

Time frame:
Baseline and Week 64
Reported as:
Mean · ng/L
Change From Baseline in Serum Inhibin B Concentration to Week 64
ng/LCorifollitropin Alfa (CFA)+Human Chorionic Gonadotropin (hCG)
Baseline31.92 ± 35.30
Baseline to Week 6491.46 ± 59.25
SecondaryGrowth Velocity at Week 36

Growth velocity is the rate of change in height measurement and is a marker for pubertal progress. Height was measured using a wall-mounted calibrated stadiometer. A mixed model was used to assess the overall growth velocity slope over the 36-week treatment period using the slopes estimated from an overall mixed random intercept and random slope model of height (cm) and time (yr) and age as covariates.

Time frame:
Week 36
Reported as:
Least squares mean · cm/year
Growth Velocity at Week 36
cm/yearCorifollitropin Alfa (CFA)+Human Chorionic Gonadotropin (hCG)
Growth Velocity at Week 368.3 ± 1.1
SecondaryGrowth Velocity at Week 64

Growth velocity is the rate of change in height measurement and is a marker for pubertal progress. Height was measured using a wall-mounted calibrated stadiometer. A mixed model was used to assess the overall growth velocity slope over the 64-week treatment period using the slopes estimated from an overall mixed random intercept and random slope model of height (cm) and time (year) and age as covariates.

Time frame:
Week 64
Reported as:
Least squares mean · cm/year
Growth Velocity at Week 64
cm/yearCorifollitropin Alfa (CFA)+Human Chorionic Gonadotropin (hCG)
Growth Velocity at Week 647.6 ± 1.0
SecondaryChange From Baseline in Tanner Stage (TS) of Pubertal Development for Pubic Hair to Week 12, Week 36, and Week 64

Male participants were assessed clinically for pubertal development using the TS for pubic hair (range: Tanner I-V). TS describes sexual maturity stages (no better or worse outcome) as: Tanner I: prepubertal state, Tanner II: small amount of long, downy hair with slight pigmentation at the base of the penis and scrotum, Tanner III: hair becomes more coarse and curly, and begins to extend laterally, Tanner IV: adult-like hair quality, extending across pubis but sparing medial thighs and Tanner V: hair extends to medial surface of the thigh. The number of participants in each Tanner stage at baseline and categorical change from baseline in Tanner stages to Weeks 12, 36 and 64 were reported.

Time frame:
Baseline, Week 12, Week 36, and Week 64
Reported as:
Count of participants · Participants
Change From Baseline in Tanner Stage (TS) of Pubertal Development for Pubic Hair to Week 12, Week 36, and Week 64
ParticipantsCorifollitropin Alfa (CFA)+Human Chorionic Gonadotropin (hCG)
Baseline (BL) Tanner I6
BL Tanner II6
BL Tanner III1
BL Tanner IV0
BL Tanner V0
BL Tanner I to Week 12 Tanner I5
BL Tanner I to Week 12 Tanner II1
BL Tanner II to Week 12 Tanner II5
BL Tanner II to Week 12 Tanner III1
BL Tanner III to Week 12 Tanner III1
BL Tanner I to Week 36 Tanner II2
BL Tanner I to Week 36 Tanner III4
BL Tanner II to Week 36 Tanner II2
BL Tanner II to Week 36 Tanner III4
BL Tanner III to Week 36 Tanner IV1
BL Tanner I to Week 64 Tanner III3
BL Tanner I to Week 64 Tanner IV1
BL Tanner I to Week 64 Tanner V2
BL Tanner II to Week 64 Tanner III1
BL Tanner II to Week 64 Tanner IV3
BL Tanner II to Week 64 Tanner V1
BL Tanner II to Week 64 Unknown1
BL Tanner III to Week 64 Tanner IV1
SecondaryChange From Baseline in TS of Pubertal Development for Genital Growth to Week 12, Week 36, and Week 64

Male participants were assessed clinically for pubertal development using TS for genital growth (range: Tanner I-V). TS describes sexual maturity stages (no better or worse outcome) as: Tanner I: prepubertal (TV \<1.5 ml; small penis), Tanner II: TV 1.6-6ml; skin on scrotum thins, reddens and enlarges; penis length unchanged, Tanner III: TV 6-12ml; scrotum enlarges further; penis begins to lengthen Tanner IV: TV 12-20ml; scrotum enlarges further and darkens; penis increases in length and circumference, and Tanner V: TV \>20ml; adult scrotum and penis. The number of participants in each Tanner stage at baseline and categorical change from baseline in Tanner stages to Weeks 12, 36 and 64 were reported.

Time frame:
Baseline, Week 12, Week 36, and Week 64
Reported as:
Count of participants · Participants
Change From Baseline in TS of Pubertal Development for Genital Growth to Week 12, Week 36, and Week 64
ParticipantsCorifollitropin Alfa (CFA)+Human Chorionic Gonadotropin (hCG)
Baseline (BL) Tanner I12
BL Tanner II1
BL Tanner III0
BL Tanner IV0
BL Tanner V0
BL Tanner I to Week 12 Tanner I9
BL Tanner I to Week 12 Tanner II3
BL Tanner II to Week 12 Tanner II1
BL Tanner I to Week 36 Tanner I2
BL Tanner I to Week 36 Tanner II1
BL Tanner I to Week 36 Tanner III8
BL Tanner I to Week 36 Tanner IV1
BL Tanner II to Week 36 Tanner II1
BL Tanner I to Week 64 Tanner II1
BL Tanner I to Week 64 Tanner III4
BL Tanner I to Week 64 Tanner IV4
BL Tanner I to Week 64 Tanner V2
BL Tanner I to Week 64 Unknown1
BL Tanner II to Week 64 Tanner III1
SecondaryMean Serum Concentration of CFA

Blood samples were collected at pre-specified time points (Day 1 (predose, 6-24 hours postdose after 1st dose), Day 3 (32-52 hours postdose after 1st dose), Day 5 (72-120 hours postdose after 1st dose), Day 8 (144-192 hours postdose after 1st dose), Day 11 (216-244 hours postdose after 1st dose), Day 29 (predose prior to 2nd dose; no hCG), Day 85 (predose, prior to 4th dose; no hCG), Day 169 (predose prior to 7th dose; with hCG co-administration), Day 253 (predose prior to 10th dose with hCG co-administration), Day 337 (predose prior to 13th dose; with hCG co-administration), Days 449 and 456 (postdose)) to report the mean serum concentration of CFA.

Time frame:
Day 1: predose, 6-24 hours postdose; Day 3: 32-52 hours postdose; Day 5: 72-120 hours postdose; Day 8: 144-192 hours postdose; Day 11: 216-244 hours postdose; Days 29, 85, 169, 253, 337: predose; Days 449, 456: postdose
Reported as:
Mean · ng/L
Mean Serum Concentration of CFA
ng/LCorifollitropin Alfa (CFA)+Human Chorionic Gonadotropin (hCG)
Predose Day 10.0 ± 0.0
Postdose Day 1 (6-24 hours)4100 ± 2630
Postdose Day 3 (32-52 hours)5880 ± 1640
Postdose Day 5 (72-120 hours)4240 ± 1180
Postdose Day 8 (144-192 hours)2110 ± 864
Postdose Day 11 (216-264 hours)1150 ± 655
Predose Day 29480 ± 348
Predose Day 85695 ± 1310
Predose Day 169691 ± 1060
Predose Day 253301 ± 297
Predose Day 337556 ± 1260
Postdose Day 449864 ± 1290
Postdose Day 4560.0 ± 0.0
SecondaryChange From Baseline in Testicular Echogenicity to Week 12, Week 36, and Week 64

Testicular Echogenicity was determined by evaluating the sonographic patterns obtained on testicular ultrasound of right and left testes at baseline, Week 12, Week 36 and 64. The sonographic patterns were assessed by central imaging unit by an independent radiologist and categorized as Hypoechoic (decreased echogenicity as compared to echogenicity at baseline), Isoechoic (same echogenicity as compared to echogenicity at baseline) and Hyperechoic (increased echogenicity as compared to echogenicity at baseline). The number of participants with a sonographic pattern at Weeks 12, 36 and 64 were reported.

Time frame:
Baseline, Week 12, Week 36, and Week 64
Reported as:
Count of participants · Participants
Change From Baseline in Testicular Echogenicity to Week 12, Week 36, and Week 64
ParticipantsCorifollitropin Alfa (CFA)+Human Chorionic Gonadotropin (hCG)
Left Testes: Baseline (BL) to Week 12: Hypoechoic2
Left Testes: BL to Week 12: Isoechoic10
Left Testes: BL to Week 12: Hyperechoic1
Right Testes: BL to Week 12: Hypoechoic1
Right Testes: BL to Week 12: Isoechoic12
Left Testes: BL to Week 36: Hypoechoic2
Left Testes: BL to Week 36: Isoechoic10
Left Testes: BL to Week 36: Hyperechoic1
Right Testes: BL to Week 36: Hypoechoic1
Right Testes: BL to Week 36: Isoechoic9
Right Testes: BL to Week 36: Hyperechoic3
Left Testes: BL to Week 64: Hypoechoic2
Left Testes: BL to Week 64: Isoechoic8
Left Testes: BL to Week 64: Hyperechoic3
Right Testes: BL to Week 64: Isoechoic10
Right Testes: BL to Week 64: Hyperechoic3
SecondaryChange From Baseline in Luteinizing Hormone (LH) to Week 12, Week 36, and Week 64

LH is a gonadotropin secreted from the anterior pituitary and is a marker for spontaneous puberty. Blood samples were collected at baseline, Week 12, Week 36 and Week 64 to report the mean change from baseline in LH level to Weeks 12, 36 and 64.

Time frame:
Baseline, Week 12, Week 36, and Week 64
Reported as:
Mean · IU/L
Change From Baseline in Luteinizing Hormone (LH) to Week 12, Week 36, and Week 64
IU/LCorifollitropin Alfa (CFA)+Human Chorionic Gonadotropin (hCG)
Baseline0.25 ± 0.24
Baseline to Week 12-0.08 ± 0.15
Baseline to Week 36-0.13 ± 0.25
Baseline to Week 64-0.14 ± 0.25
SecondaryChange From Baseline in Calculated Free Testosterone (T) to Week 12, Week 36, and Week 64

Blood samples were collected at baseline, Week 12, Week 36 and Week 64 to report the mean change from baseline in T level to Weeks 12, 36 and 64. The change from baseline in T level to Week 12, 36, and 64 could not be calculated as planned because only 2 participants had baseline T level values which were insufficient to provide the trend change from baseline in T level to Week 12, 36, and 64.

Time frame:
Baseline, Week 12, Week 36, and Week 64

No measurements were reported for this outcome.

SecondaryChange From Baseline in Total Testosterone (Total T) to Week 12, Week 36, and Week 64

Total T is a marker for progress of puberty in males. Total T levels increase during puberty as the testes respond to the gonadotropins. Blood samples were collected at baseline, Week 12, Week 36 and Week 64 post dose to report the mean change from baseline in Total T level to Weeks 12, 36 and 64. A negative value indicated a lower Total T level.

Time frame:
Baseline, Week 12, Week 36, and Week 64
Reported as:
Mean · ug/L
Change From Baseline in Total Testosterone (Total T) to Week 12, Week 36, and Week 64
ug/LCorifollitropin Alfa (CFA)+Human Chorionic Gonadotropin (hCG)
Baseline0.11 ± 0.12
Baseline to Week 12-0.01 ± 0.07
Baseline to Week 364.87 ± 3.97
Baseline to Week 645.31 ± 3.31
SecondaryChange From Baseline in Estradiol (E2) to Week 12, Week 36, and Week 64

E2 levels rise during puberty in males when some of the T secreted is aromatized. Blood samples were collected at baseline, Week 12, Week 36 and Week 64 to report the mean change from baseline in E2 level to Weeks 12, 36 and 64. A positive value indicated a higher E2 level.

Time frame:
Baseline, Week 12, Week 36, and Week 64
Reported as:
Mean · ng/L
Change From Baseline in Estradiol (E2) to Week 12, Week 36, and Week 64
ng/LCorifollitropin Alfa (CFA)+Human Chorionic Gonadotropin (hCG)
Baseline9.51 ± 0.00
Baseline to Week 120.81 ± 2.90
Baseline to Week 3637.57 ± 28.73
Baseline to Week 6445.58 ± 41.09
SecondaryChange From Baseline in Sex Hormone-Binding Globulin (SHBG) to Week 12, Week 36, and Week 64

SHBG is a blood protein that controls the amount of T body tissues in males. SHBG is regulated by the ratio of T and E2 levels in addition to other factors (thyroid hormone status, dietary factors, certain diseases and medications). Blood samples were collected at baseline, Week 12, Week 36 and Week 64 to report the mean change from baseline in SHBG level to Weeks 12, 36 and 64. A negative value indicated a lower SHBG level.

Time frame:
Baseline, Week 12, Week 36, and Week 64
Reported as:
Mean · ug/dL
Change From Baseline in Sex Hormone-Binding Globulin (SHBG) to Week 12, Week 36, and Week 64
ug/dLCorifollitropin Alfa (CFA)+Human Chorionic Gonadotropin (hCG)
Baseline1.53 ± 0.91
Baseline to Week 120.04 ± 0.45
Baseline to Week 36-0.53 ± 0.73
Baseline to Week 64-0.68 ± 0.76
SecondaryChange From Baseline in Anti-Müllerian Hormone (AMH) to Week 12, Week 36, and Week 64

AMH is a marker for progress of puberty in males. Blood samples were collected at baseline, Week 12, Week 36 and Week 64 to report the mean change from baseline in AMH level to Weeks 12, 36 and 64. A negative value indicated a lower AMH level.

Time frame:
Baseline, Week 12, Week 36, and Week 64
Reported as:
Mean · ug/L
Change From Baseline in Anti-Müllerian Hormone (AMH) to Week 12, Week 36, and Week 64
ug/LCorifollitropin Alfa (CFA)+Human Chorionic Gonadotropin (hCG)
Baseline23.62 ± 11.07
Baseline to Week 1217.98 ± 8.39
Baseline to Week 36-10.23 ± 15.69
Baseline to Week 64-15.83 ± 11.58

Adverse events

Collected over All-cause mortality, serious and non-serious AEs were collected for up to approximately 71 Weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Corifollitropin Alfa (CFA)+Human Chorionic Gonadotropin (hCG)0/17 (0%)1/17 (5.9%)16/17 (94.1%)
Most frequent serious events
Most frequent serious events
EventCorifollitropin Alfa (CFA)+Human Chorionic Gonadotropin (hCG)
CraniopharyngiomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/17
Most frequent other events
Showing 10 of 52
Most frequent other events
EventCorifollitropin Alfa (CFA)+Human Chorionic Gonadotropin (hCG)
Oestradiol increasedInvestigations5/17
SpermatoceleReproductive system and breast disorders5/17
Blood testosterone increasedInvestigations4/17
HeadacheNervous system disorders4/17
DiarrhoeaGastrointestinal disorders2/17
VomitingGastrointestinal disorders2/17
NasopharyngitisInfections and infestations2/17
Upper respiratory tract infectionInfections and infestations2/17
Blood testosterone decreasedInvestigations2/17
Blood testosterone free increasedInvestigations2/17

Baseline characteristics

Male participants with Hypogonadotropic Hypogonadism (HH) aged 14 to \<18 years were enrolled in the study.

Age, Continuous
Age, Continuous(years)Corifollitropin Alfa (CFA)+Human Chorionic Gonadotropin (hCG)
Mean15.5 ± 0.9
Sex: Female, Male
Sex: Female, Male(Participants)Corifollitropin Alfa (CFA)+Human Chorionic Gonadotropin (hCG)
Female0
Male17
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Corifollitropin Alfa (CFA)+Human Chorionic Gonadotropin (hCG)
Hispanic or Latino4
Not Hispanic or Latino13
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Corifollitropin Alfa (CFA)+Human Chorionic Gonadotropin (hCG)
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White16
More than one race1
Unknown or Not Reported0
Testicular Volume (TV)
Testicular Volume (TV)(mL)Corifollitropin Alfa (CFA)+Human Chorionic Gonadotropin (hCG)
Mean2.2 ± 1.9
08

Study locations

15 sites
  • Centro de Diabetes Curitiba ( Site 0012)
    Curitiba, 80810-040, Brazil
  • Hospital de Clinicas de Porto Alegre ( Site 0014)
    Porto Alegre, 90035-903, Brazil
  • Hosp das Clinicas da Faculdade de Medicina da Univ de Sao Paulo ( Site 0015)
    Sao Paulo, 05403-000, Brazil
  • Rigshospitalet, University department of Growth and Reproduction ( Site 0051)
    Copenhagen, 2100, Denmark
  • AOU Careggi ( Site 0042)
    Firenze, 50139, Italy
  • Policlinico Umberto I ( Site 0043)
    Roma, 00161, Italy
  • IRCCS Ospedale Pediatrico Bambino Gesu ( Site 0044)
    Roma, 00165, Italy
  • Instituto Nacional de Pediatria ( Site 0007)
    Mexico City, 04530, Mexico
  • Hospital Infantil de Mexico Federico Gomez ( Site 0006)
    Mexico City, 06720, Mexico
  • Kazan State Medical University ( Site 0024)
    Kazan, 420048, Russian Federation
  • Federal State Budget Institution Endocrinological Research Center ( Site 0021)
    Moscow, 117036, Russian Federation
  • City children polyclinic #44 ( Site 0025)
    Saint Petersburg, 191144, Russian Federation
  • St.Petersburg State Pediatric Medical University ( Site 0023)
    Saint Petersburg, 194100, Russian Federation
  • Republic Children Clinical Hospital ( Site 0022)
    Ufa, 450106, Russian Federation
  • Little Company of Mary Hospital ( Site 0017)
    Pretoria, 0181, South Africa
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2017 to primary completion in May 2020, 39 months.

Results were first posted in Apr 2021, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 11, 2017
First posted
Jan 12, 2017
StartActual
Feb 2, 2017
Primary completionActual
May 5, 2020
CompletionActual
May 5, 2020
Results first posted
Apr 8, 2021
Last update
May 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03019575
Lead sponsor
Organon and Co
Responsible party
Sponsor
First posted
Jan 12, 2017
Start date
Feb 2, 2017
Primary completion
May 5, 2020
Completion
May 5, 2020
Results posted
Apr 8, 2021
Last update
May 23, 2024

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Corifollitropin alfa · Chorionic Gonadotropin

Start the discussion